IRL757 Ph 1 approved by reg. authority
Today IRLAB has announced the approval from the Swedish Medical Products Agency to conduct a Ph 1 study with its apathy drug candidate IRL757. The study will investigate the PK, safety and tolerability of IRL757, starting with single ascending doses (SAD) (part 1), followed by multiple ascending doses (MAD) (part 2). The impact of food intake on the drug's PK profile will also be evaluated.The study is fully financed by the grant from the Michael J. Fox foundation, which was announced in Dec'23 (~SEK 20m). The study is expected to finish by YE'24 and read out results in Q1'25e.
Aktuellt
SENASTE
